The Novel Anti-inflammatory Compound, Lisofylline, Prevents Diabetes in Multiple Low-Dose Streptozotocin-Treated Mice.

MLA

Zandong Yang, et al. “The Novel Anti-Inflammatory Compound, Lisofylline, Prevents Diabetes in Multiple Low-Dose Streptozotocin-Treated Mice.” Pancreas, vol. 26, no. 4, May 2003, pp. e99–104. EBSCOhost, https://doi.org/10.1097/00006676-200305000-00021.

APA

Zandong Yang, Meng Chen, Lawrence B. Fialkow, Justin D. Ellett, Runpei Wu, & Jerry L. Nadler. (2003). The Novel Anti-inflammatory Compound, Lisofylline, Prevents Diabetes in Multiple Low-Dose Streptozotocin-Treated Mice. Pancreas, 26(4), e99–e104. https://doi.org/10.1097/00006676-200305000-00021

Chicago

Zandong Yang, Meng Chen, Lawrence B. Fialkow, Justin D. Ellett, Runpei Wu, and Jerry L. Nadler. 2003. “The Novel Anti-Inflammatory Compound, Lisofylline, Prevents Diabetes in Multiple Low-Dose Streptozotocin-Treated Mice.” Pancreas 26 (4): e99–104. doi:10.1097/00006676-200305000-00021.